New treatment options for HIV salvage patients: An overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists
Authors:
- Amelia HughesAHAmelia Hughes
- Tristan BarberTBTristan Barber
- Mark NelsonMNMark Nelson
- 1 July 2008
- journal article
- review article
- Published by Elsevier in Journal of Infection
- Vol. 57 (1) , 1-10
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trialThe Lancet, 2007
- Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trialThe Lancet, 2007
- Evidence of a decline in transmitted HIV-1 drug resistance in the United KingdomAIDS, 2007
- Bis‐Tetrahydrofuran: a Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors That Combat Drug ResistanceChemMedChem, 2006
- Interruption of Treatment with Individual Therapeutic Drug Classes in Adults with Multidrug‐Resistant HIV‐1 InfectionThe Journal of Infectious Diseases, 2005
- Estimating HIV‐1 Drug Resistance in Antiretroviral‐Treated Individuals in the United KingdomThe Journal of Infectious Diseases, 2005
- Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug‐Resistant HIV‐1 InfectionClinical Infectious Diseases, 2005
- An open-label assessment of TMC 125–a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistanceAIDS, 2003
- Performance of the VERSANT®HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypesFEMS Immunology & Medical Microbiology, 2003
- Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnucleoside Inhibitor TMC125Journal of the American Chemical Society, 2003